Dr Reddy's Labs shares jumped as much as 3 per cent today amid huge volumes. As of 12.38 p.m., 25,000 shares had changed hands as against its 2-week average of 18,000 shares.
Global brokerage CLSA says Dr Reddy's Labs shares may double in three years. The brokerage expects re-rating to happen in the stock as earnings of India's second biggest pharma company recovers and US regulatory issues are resolved.
The brokerage has a "buy" rating on Dr Reddy's Labs with a target price of Rs 3,735, indicating a potential upside of 22 per cent from Tuesday's closing price. However, the brokerage warned that Dr Reddy's earnings growth is likely to be weak in the first half of the current fiscal.
Dr Reddy's Labs shares have been under pressure since last November after three of its facilities received warning letter from the US drug regulator. It shares are down nearly 28 per cent from November levels.
Dr Reddy's shares closed 1.84 per cent higher at Rs 3,105.10 compared to 0.20 per cent fall in the broader Nifty.
Dr Reddy's Labs shares jumped as much as 3 per cent today amid huge volumes. As of 12.38 p.m., 25,000 shares had changed hands as against its 2-week average of 18,000 shares.
Global brokerage CLSA says Dr Reddy's Labs shares may double in three years. The brokerage expects re-rating to happen in the stock as earnings of India's second biggest pharma company recovers and US regulatory issues are resolved.
The brokerage has a "buy" rating on Dr Reddy's Labs with a target price of Rs 3,735, indicating a potential upside of 22 per cent from Tuesday's closing price. However, the brokerage warned that Dr Reddy's earnings growth is likely to be weak in the first half of the current fiscal.
Dr Reddy's Labs shares have been under pressure since last November after three of its facilities received warning letter from the US drug regulator. It shares are down nearly 28 per cent from November levels.
Dr Reddy's shares closed 1.84 per cent higher at Rs 3,105.10 compared to 0.20 per cent fall in the broader Nifty.
Dr Reddy's Labs shares jumped as much as 3 per cent today amid huge volumes. As of 12.38 p.m., 25,000 shares had changed hands as against its 2-week average of 18,000 shares.
Global brokerage CLSA says Dr Reddy's Labs shares may double in three years. The brokerage expects re-rating to happen in the stock as earnings of India's second biggest pharma company recovers and US regulatory issues are resolved.
The brokerage has a "buy" rating on Dr Reddy's Labs with a target price of Rs 3,735, indicating a potential upside of 22 per cent from Tuesday's closing price. However, the brokerage warned that Dr Reddy's earnings growth is likely to be weak in the first half of the current fiscal.
Dr Reddy's Labs shares have been under pressure since last November after three of its facilities received warning letter from the US drug regulator. It shares are down nearly 28 per cent from November levels.
Dr Reddy's shares closed 1.84 per cent higher at Rs 3,105.10 compared to 0.20 per cent fall in the broader Nifty.
Sign Up with Google
RECOMMENDED FOR YOU
Multibagger Paras Defence Shares Jump Over 9% After Stock Split
Jul 04, 2025
Raymond Shares Jump For Third Session After Demerged Realty Arm Lists
Jul 01, 2025
IDBI Bank Shares Jump Nearly 5% After Disinvestment Said To Be In Final Phase
Jun 30, 2025
Multibagger: Textile Maker Arvind Sees Staggering 1000% Jump In Five Years — Buy, Sell Or Hold?
Jun 26, 2025
POPULAR